Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.49 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 5/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6106438 | 0.91 | ADORA1 (0.48) | IKBKBMAPK10MAPK8MAPK9EIF2AK2 | |
| SCHEMBL6105435 | 0.91 | MAPK10 (0.52) | MAPK10MAPK8MAPK9GSK3BCDK4 | |
| SCHEMBL6106109 | 0.91 | ADORA1 (0.48) | IKBKBMAPK10MAPK8MAPK9EIF2AK2 | |
| SCHEMBL6106728 | 0.91 | ADORA1 (0.48) | IKBKBMAPK10MAPK8MAPK9EIF2AK2 | |
| SCHEMBL5456838 | 0.90 | CSNK1D (0.51) | MAPK10MAPK8MAPK9GSK3BCDK4 | |
| SCHEMBL6105772 | 0.90 | CDK4 (0.44) | MAPK10MAPK8MAPK9EIF2AK2GSK3B | |
| SCHEMBL5211093 | 0.90 | CDK4 (0.46) | MAPK10MAPK8MAPK9EIF2AK2GSK3B | |
| SCHEMBL6108194 | 0.90 | CDK4 (0.46) | MAPK10MAPK8MAPK9EIF2AK2GSK3B | |
| SCHEMBL5462491 | 0.90 | CSNK1D (0.51) | MAPK10MAPK8MAPK9GSK3BCDK4 | |
| SCHEMBL6105242 | 0.90 | CDK4 (0.46) | MAPK10MAPK8MAPK9EIF2AK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | claimed |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | CYP3A5, CYP2C19, CYP3A4 | IKBKB 3058/4885MAPK10 2440/4885MAPK8 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.